No abstract

Human mesenchymal stem cells (MSCs) are multipotential and are detected in bone marrow (BM), adipose tissue, placenta, and umbilical cord blood (UCB). In this study, we examined the ability of UCB-derived MSCs (UCB-MSCs) to support ex vivo expansion of hematopoietic stem/progenitor cells (HSPCs) from UCB and the engraftment of expanded HSPCs in NOD/SCID mice. The result showed that UCB-MSCs supported the proliferation and differentiation of CD34+ cells in vitro. The number of expanded total nucleated cells (TNCs) in MSC-based culture was twofold higher than cultures without MSC (control cultures). UCB-MSCs increased the expansion capabilities of CD34+ cells, long-term culture-initiating cells (LTC-ICs), granulocyte-macrophage colony-forming cells (GM-CFCs), and high proliferative potential colony-forming cells (HPP-CFCs) compared to control cultures. The expanded HSPCs were transplanted into lethally irradiated NOD/SCID mice to assess the effects of expanded cells on hematopoietic recovery. The number of white blood cells (WBCs) in the peripheral blood of mice transplanted with expanded cells from both the MSC-based and control cultures returned to pretreatment levels at day 25 posttransplant and then decreased. The WBC levels returned to pretreatment levels again at days 45-55 posttransplant. The level of human CD45+ cell engraftment in primary recipients transplanted with expanded cells from the MSC-based cultures was significantly higher than recipients transplanted with cells from the control cultures. Serial transplantation demonstrated that the expanded cells could establish long-term engraftment of hematopoietic cells. UCB-MSCs similar to those derived from adult bone marrow may provide novel targets for cellular and gene therapy.

No abstract

Anomalous runtime behavior detection is one of the most important tasks for performance diagnosis in High Performance Computing (HPC). Most of the existing methods find anomalous executions based on the properties of individual functions, such as execution time. However, it is insufficient to identify abnormal behavior without taking into account the context of the executions, such as the invocations of children functions and the communications with other HPC nodes. We improve upon the existing anomaly detection approaches by utilizing the call stack structures of the executions, which record rich temporal and contextual information. With our call stack tree (CSTree) representation of the executions, we formulate the anomaly detection problem as finding anomalous tree structures in a call stack forest. The CSTrees are converted to vector representations using our proposed stack2vec embedding. Structural and temporal visualizations of CSTrees are provided to support users in the identification and verification of the anomalies during an active anomaly detection process. Three case studies of real-world HPC applications demonstrate the capabilities of our approach.

Abstract-Previous studies on E-transaction time-series have mainly focused on finding temporal trends of transaction behavior. Interesting transactions that are time-stamped and situation-relevant may easily be obscured in a large amount of information. This paper proposes a visual analytics system, Visual Analysis of E-transaction Time-Series (VAET), that allows the analysts to interactively explore large transaction datasets for insights about time-varying transactions. With a set of analyst-determined training samples, VAET automatically estimates the saliency of each transaction in a large time-series using a probabilistic decision tree learner. It provides an effective time-of-saliency (TOS) map where the analysts can explore a large number of transactions at different time granularities. Interesting transactions are further encoded with KnotLines, a compact visual representation that captures both the temporal variations and the contextual connection of transactions. The analysts can thus explore, select, and investigate knotlines of interest. A case study and user study with a real E-transactions dataset (26 million records) demonstrate the effectiveness of VAET.

The human induced pluripotent stem cell (iPSC) technique promises to provide an unlimited, reliable source of genetically matched pluripotent cells for personalized therapy and disease modeling. Recently, it is observed that cells with ring chromosomes 13 or 17 autonomously correct the defects via compensatory uniparental disomy during cellular reprogramming to iPSCs. This breakthrough finding suggests a potential therapeutic approach to repair large-scale chromosomal aberrations. However, due to the scarceness of ring chromosome samples, the reproducibility of this approach in different individuals is not carefully evaluated yet. Moreover, the underlying mechanism and the applicability to other types of chromosomal aberrations remain unknown. Here we generated iPSCs from four 45,X chorionic villous fibroblast lines and found that only one reprogrammed line acquired 46,XX karyotype via uniparental disomy of the entire X chromosome. The karyotype correction was reproducible in the same cell line by either retroviral or episomal reprogramming. The karyotype-corrected iPSCs were subject to X chromosome inactivation and obtained better colony morphology and higher proliferation rate than other uncorrected ones. Further transcriptomic comparison among the fibroblast lines identified a distinct expression pattern of cell cycle regulators in the uncorrectable ones. These findings demonstrate that the iPSC technique holds the potential to correct X monosomy, but the correction rate is very low, probably due to differential regulation of cell cycle genes between individuals. Our data strongly suggest that more systematic investigations are needed before defining the iPSC technique as a novel means of chromosome therapy.

No abstract

The p21-activated kinase 4 (PAK4) is a member of the PAKs family. It is overexpressed in multiple tumor tissues. Pharmacological inhibition of PAK4 attenuates proliferation, migration, and invasion of cancer cells. Recent studies revealed that inhibition of PAK4 sensitizes immunotherapy which has been extensively exploited as a new strategy to treat cancer. In the past few years, a large number of PAK4 inhibitors have been reported. Of note, the allosteric inhibitor KPT-9274 has been tested in phase Ⅰ clinic trials. Herein, we provide an update on recent research progress on the PAK4 mediated signaling pathway and highlight the development of the PAK4 small molecular inhibitors in recent 5 years. Meanwhile, challenges, limitations, and future developmental directions will be discussed as well.